ADXN · Addex Therapeutics Ltd American Depositary Shares
View on chartInsiders & Stakes
| Dyer Timothy Mark CHIEF EXECUTIVE OFFICER | ▲ Buy | Grant | 16,848,979 Shares held | 9/2/2026 | View profile |
| Lawton Vincent Michael Director | ▲ Buy | Grant | 2,507,987 Shares held | 9/2/2026 | View profile |
| Hill Raymond George Director | ▲ Buy | Grant | 1,365,532 Shares held | 9/2/2026 | View profile |
| Mills Roger CHIEF MEDICAL OFFICER | ▲ Buy | Grant | 785,976 Shares held | 9/2/2026 | View profile |
| Kalinichev Mikhail HEAD OF TRANSLATIONAL SCIENCE | ▲ Buy | Grant | 306,765 Shares held | 9/2/2026 | View profile |
| Isaac Manke Director | ▲ Buy | Grant | 219,561 Shares held | 9/2/2026 | View profile |
| Nunn Jason Raleigh Director | ▲ Buy | Grant | 219,561 Shares held | 9/2/2026 | View profile |
Transaction History
| Dyer Timothy Mark | ▲ Buy | Grant | 16,413,787 | $0 | 9/2/2026 |
| Dyer Timothy Mark | ▼ Sell | Other | 16,413,787 | $0 | 9/2/2026 |
| Isaac Manke | ▲ Buy | Grant | 219,561 | $0 | 9/2/2026 |
| Lawton Vincent Michael | ▼ Sell | Other | 2,507,487 | $0 | 9/2/2026 |
| Lawton Vincent Michael | ▲ Buy | Grant | 2,507,487 | $0 | 9/2/2026 |
| Hill Raymond George | ▼ Sell | Other | 1,365,532 | $0 | 9/2/2026 |
| Hill Raymond George | ▲ Buy | Grant | 1,365,532 | $0 | 9/2/2026 |
| Kalinichev Mikhail | ▲ Buy | Grant | 306,765 | $0 | 9/2/2026 |
| Nunn Jason Raleigh | ▼ Sell | Other | 219,561 | $0 | 9/2/2026 |
| Kalinichev Mikhail | ▼ Sell | Other | 306,765 | $0 | 9/2/2026 |
| Mills Roger | ▼ Sell | Other | 392,837 | $0 | 9/2/2026 |
| Nunn Jason Raleigh | ▲ Buy | Grant | 219,561 | $0 | 9/2/2026 |
| Mills Roger | ▲ Buy | Grant | 392,837 | $0 | 9/2/2026 |
| Isaac Manke | ▼ Sell | Other | 219,561 | $0 | 9/2/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Addex Therapeutics Reports Q2 2026 Results and Management Changes
Addex Therapeutics announced executive management changes alongside its Q2 2026 earnings report. The company reported sales of $12,650, a decrease from $44,031 in the same period last year. Additionally, the company provided an update on its corporate status during the half-year results release.
Addex Therapeutics Reports Q2 2026 Results and Management Changes. Addex Therapeutics announced executive management changes alongside its Q2 2026 earnings report. The company reported sales of $12,650, a decrease from $44,031 in the same period last year. Additionally, the company provided an update on its corporate status during the half-year results release.